Koumegawa J, Kawahara J, Kubo K, Amano K, Wakimoto N, Takahashi K, Juji T, Takaku F
Pharmaceuticals Department, Kirin Brewery Co., Ltd., Tokyo, Japan.
Int J Cell Cloning. 1990 Mar;8(2):97-106. doi: 10.1002/stem.5530080203?.
In order to evaluate the possibility of using recombinant human erythropoietin (rhEpo) for the prevention and correction of anemia due to blood loss and as an adjuvant for autologous blood transfusion, its preventive and therapeutic effects were evaluated in beagles in which anemia was induced by repeated phlebotomies. Two hundred U/kg of rhEpo were administered i.v. four or nine times every two weeks for six weeks. Phlebotomies (25 ml/kg of body weight) were conducted three times at two-week intervals. rhEpo was found to successfully prevent and correct anemia caused by the phlebotomies. Concurrent administration of iron increased efficacy. The findings obtained in the present study suggest that rhEpo is useful both for the treatment of anemia caused by blood loss due to surgery and as an adjuvant therapy for pre-deposit autologous blood transfusion.
为了评估使用重组人促红细胞生成素（rhEpo）预防和纠正失血引起的贫血以及作为自体输血辅助剂的可能性，在通过反复放血诱导贫血的比格犬中评估了其预防和治疗效果。每两周静脉注射200 U/kg的rhEpo，共注射4次或9次，持续6周。每两周进行一次放血（25 ml/kg体重），共进行3次。结果发现rhEpo成功预防和纠正了放血引起的贫血。同时给予铁剂可提高疗效。本研究获得的结果表明，rhEpo可用于治疗手术失血引起的贫血以及作为预存式自体输血的辅助治疗。
